## Margaret Littlejohn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6322421/publications.pdf

Version: 2024-02-01

304743 265206 48 1,930 22 42 citations h-index g-index papers 50 50 50 2355 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology, 2010, 51, 1933-1944.	7.3	366
2	The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Research, 2007, 76, 168-177.	4.1	141
3	Longâ€Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection. Journal of Infectious Diseases, 2001, 184, 1236-1245.	4.0	140
4	The evolution and clinical impact of hepatitis B virus genome diversity. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 618-634.	17.8	107
5	Insights From Deep Sequencing of the HBV Genomeâ€"Unique, Tiny, and Misunderstood. Gastroenterology, 2019, 156, 384-399.	1.3	92
6	Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a021360.	6.2	84
7	Possible origins and evolution of the hepatitis B virus (HBV). Seminars in Cancer Biology, 2013, 23, 561-575.	9.6	76
8	Patterns and Causes of Suboptimal Response to Tenofovir-Based Therapy in Individuals Coinfected With HIV and Hepatitis B Virus. Clinical Infectious Diseases, 2013, 56, e87-e94.	5 <b>.</b> 8	69
9	A Divergent Hepatitis D-Like Agent in Birds. Viruses, 2018, 10, 720.	3.3	69
10	SEQHEPB: A sequence analysis program and relational database system for chronic hepatitis B. Antiviral Research, 2007, 75, 64-74.	4.1	68
11	<i>In Vitro</i> Studies Show that Sequence Variability Contributes to Marked Variation in Hepatitis B Virus Replication, Protein Expression, and Function Observed across Genotypes. Journal of Virology, 2016, 90, 10054-10064.	3.4	49
12	The molecular epidemiology of hepatitis <scp>B</scp> in the Indigenous people of northern <scp>A</scp> ustralia. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1234-1241.	2.8	47
13	Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut, 2017, 66, 2013-2023.	12.1	42
14	Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals. PLoS ONE, 2013, 8, e61297.	2.5	41
15	Molecular virology of hepatitis B virus, subâ€genotype C4 in northern Australian Indigenous populations. Journal of Medical Virology, 2014, 86, 695-706.	5.0	38
16	Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences. Journal of General Virology, 2020, 101, 271-283.	2.9	38
17	Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals. Aids, 2007, 21, 1701-1710.	2.2	36
18	Quantification of HBV Covalently Closed Circular DNA from Liver Tissue by Real-Time PCR., 2004, 95, 41-50.		31

#	Article	IF	CITATIONS
19	Molecular and clinical characteristics of hepatitis B virus in Korea. Journal of Medical Virology, 2010, 82, 1126-1134.	5.0	31
20	HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing. Virology, 2010, 405, 539-547.	2.4	28
21	<scp>ALT</scp> flares during nucleotide analogue therapy are associated with <scp>HB</scp> sAg loss in genotype A <scp>HB</scp> eAgâ€positive chronic hepatitis B. Liver International, 2018, 38, 1760-1769.	3.9	26
22	Tracing Ancient Human Migrations into Sahul Using Hepatitis B Virus Genomes. Molecular Biology and Evolution, 2019, 36, 942-954.	8.9	26
23	Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance. Hepatology, 2008, 48, 741-749.	7.3	24
24	Molecular epidemiology of hepatitis delta virus in the Western Pacific region. Journal of Clinical Virology, 2014, 61, 34-39.	3.1	23
25	Hepatitis Delta Virus (HDV) and Delta-Like Agents: Insights Into Their Origin. Frontiers in Microbiology, 2021, 12, 652962.	3.5	22
26	Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection—Lessons for Functional HBV Cure?. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 527-533.	2.1	20
27	Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microbial Genomics, 2021, 7, .	2.0	16
28	Stopping nucleot(s)ide analogues in nonâ€cirrhotic <scp>HBeAg</scp> â€negative chronic hepatitis B patients: <scp>HBsAg</scp> loss at 96 weeks is associated with low baseline <scp>HBsAg</scp> levels. Alimentary Pharmacology and Therapeutics, 2022, 56, 310-320.	3.7	16
29	Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. Aids, 2016, 30, 1597-1606.	2.2	15
30	Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing. Journal of Medical Virology, 2022, 94, 642-648.	5.0	14
31	Origins and Evolution of the Primate Hepatitis B Virus. Frontiers in Microbiology, 2021, 12, 653684.	3.5	14
32	Molecular characterization of hepatitis B virus (HBV) in African children living in Australia identifies genotypes and variants associated with poor clinical outcome. Journal of General Virology, 2018, 99, 1103-1114.	2.9	12
33	Hepatitis B and D in the Pacific Islands of Kiribati. Journal of Clinical Virology, 2020, 129, 104527.	3.1	11
34	In vitro replication phenotype of a novel (â°'1G) hepatitis B virus variant associated with HIV coâ€infection. Journal of Medical Virology, 2012, 84, 1166-1176.	5.0	10
35	Sub-optimal protection against past hepatitis B virus infection where subtype mismatch exists between vaccine and circulating viral genotype in northern Australia. Vaccine, 2018, 36, 3533-3540.	3.8	10
36	Factors Associated with Elevated ALT in an International HIV/HBV Co-Infected Cohort on Long-Term HAART. PLoS ONE, 2011, 6, e26482.	2.5	10

#	Article	IF	CITATIONS
37	Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. Hepatology, 2021, 73, 1652-1670.	7.3	9
38	HBV variants are common in the â€~immuneâ€ŧolerant' phase of chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 1061-1070.	2.0	8
39	Genotypic profiles of hepatitis B in African immigrants and their clinical relevance. Journal of Medical Virology, 2017, 89, 1000-1007.	5.0	7
40	Hepatitis B among immigrants from Myanmar: Genotypes and their clinical relevance. Journal of Medical Virology, 2018, 90, 271-276.	5.0	7
41	Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia. Internal Medicine Journal, 2018, 48, 1308-1317.	0.8	7
42	Secreted hepatitis B virus splice variants differ by <scp>HBV</scp> genotype and across phases of chronic hepatitis B infection. Journal of Viral Hepatitis, 2022, 29, 604-615.	2.0	6
43	Towards Genotype-Specific Care for Chronic Hepatitis B: The First 6 Years Follow Up From the CHARM Cohort Study. Open Forum Infectious Diseases, 2019, 6, ofz469.	0.9	5
44	Point of care and oral fluid hepatitis B testing in remote Indigenous communities of northern Australia. Journal of Viral Hepatitis, 2020, 27, 407-414.	2.0	5
45	Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models. Cell Death and Disease, 2021, 12, 641.	6.3	4
46	A novel hepatitis <scp>B</scp> virus <scp>S</scp> gene insertion associated with reduced humoral immunity and diagnostic escape. Internal Medicine Journal, 2014, 44, 709-710.	0.8	2
47	Antiviral drug resistance and hepatitis B: a continuing public health problem. Antiviral Therapy, 2017, 22, 643-644.	1.0	1
48	Molecular Phylogenetics of Hepatitis D Virus in New Zealand and the Implications for Pacific Island Countries. Intervirology, 2021, 64, 102-107.	2.8	0